A
A
A
Print

Characteristics associated with migraines that are long in duration and/or recur:

  • Migraine symptoms may last up to 72 hours1,3
  • In one clinical study, it was documented that 65.6% of patients had headache duration up to 24 hours1
  • The same study reported that 34.4% of patients experienced headache that lasted 24 to 72 hours1
  • Migraine headache can be of longer duration among women compared to men1
  • Recurrence is generally defined as the return of a migraine within 24 hours after initial relief2,4
  • In one clinical study, a substantial number of patients (43.8%) reported headache recurrence after initial relief1

Of the estimated 28 million Americans who suffer migraines, approximately 21 million are women5

Common signs and symptoms of a migraine attack with or without aura may include:

  • Head pain and aching3
  • Light sensitivity3
  • Nausea3
  • Vomiting3
  • Vision change3
  • Sound sensitivity3

The most common side effects associated with the use of FROVA are dizziness, fatigue, paresthesia, flushing, headache, dry mouth, hot or cold sensation, skeletal pain, chest pain, and dyspepsia.
+ View references
  1. Kelman L. Pain characteristics of the acute migraine attack. Headache. 2006;46(6):942-953. doi:10.1111/j.1526-4610.2006.00443.x.
  2. Malik SN, Hopkins M, Young WB, Silberstein SD. Acute migraine treatment: patterns of use and satisfaction in a clinical population. Headache. 2006;46(5):773-780. doi:10.1111/j.1526-4610.2006.00437.x.
  3. Headache Classification Subcommittee of the International Headache Society (IHS). The international classification of headache disorders, 2nd edition, 1st revision (ICHD-IIR1). http://ihs-classification.org/_downloads/mixed/ICHD-IIR1final.doc. Updated May 2005. Accessed March 5, 2009.
  4. Guidelines for controlled trials of drugs in migraine. First edition. International Headache Society Committee on Clinical Trials in Migraine. Cephalalgia. 1991;11(1):1-12.
  5. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646-657.
  6. Cady R, Elkind A, Goldstein J, Keywood C. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate to severe. Curr Med Res Opin. 2004;20(9):1465-1472. doi:10.1185/030079904X2745.
  7. Ryan R, Geraud G, Goldstein J, Cady R, Keywood C. Clinical efficacy of frovatriptan: placebo-controlled studies. Headache. 2002;42(suppl 2):S84-S92.
  8. FROVA® [package insert]. Chadds Ford, PA: Endo Pharmaceuticals, Inc; 2007.
  9. Physicians' Desk Reference. 63rd ed. Montvale, NJ: Physicians' Desk Reference Inc; 2008.
  10. RELPAX® [package insert]. New York, NY: Pfizer Inc. Available online at: https://www.pfizerpro.com/product_info/relpax_pi_clinical_pharmacology.jsp. Accessed January 8, 2009.
     

    Important Safety Information

    For more information, please see Full Prescribing Information for FROVA at http://www.frova.com/pi.